Phase 4 study of trastuzumab deruxtecan for HER2-positive solid tumors (DP-04) - Clinical Trial
Who Can Participate in the Study?
Age Group
Adults
Study Details
Full Title
[D4327R00001] Effectiveness of T-DXd across HER2-positive solid tumors in patients who have received prior systemic treatment and have no satisfactory alternative treatment options: A hybrid observational study
Principal Investigator
Medical Oncologist
Protocol Number
IRB:
PRO00118385
Phase
Phase
IV
Enrollment Status
Open for Enrollment
Participate
Call 919-668-1861
or email gi-oncology-cru@dm.duke.edu